Report
Valens Research

PODD - Embedded Expectations Analysis - 2020 02 20

 Insulet Corporation (PODD:USA) currently trades at historical highs relative to UAFRS-based (Uniform) Assets, with a 17.4x Uniform P/B, implying bullish expectations for the firm. Meanwhile, management is confident about Omnipod demand, the performance of their DME channel, and the design of DASH
 Specifically, management is confident about their progress on meeting strategic imperatives and that their third line manufacturing initiative will help lead to a successful launch of Horizon and meet global Omnipod demand. Moreover, they are confident their performance in the DME channel was stronger than expected and that DASH, the basis of the Horizon submission, is designed to be interoperable
Underlying
Insulet Corporation

Insulet is engaged in the development, manufacturing and sale of its Omnipod? System, an insulin delivery system for people with insulin-dependent diabetes, which consists of two product lines: the Omnipod Insulin Management System and Omnipod DASH? Insulin Management System. The Omnipod System features a self-adhesive disposable tubeless Pod, which is worn on the body and provides up to three days of non-stop insulin delivery without the need to see or handle a needle, and a handheld Personal Diabetes Manager. The Omnipod System communicates wirelessly, provides for automated cannula insertion and eliminates the need for multiple daily injection therapy or the use of pump and tubing.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch